T uberous sclerosis complex (TSC) is a developmental disorder caused by mutations in the TSC1 or TSC2 genes 1,2 . TSC affects multiple systems causing nonmalignant hamartomas that can affect the skin, heart, kidney, lung, and brain 3 . Among the most debilitating aspects of TSC are the neurological symptoms. Approximately 90% of TSC patients have epilepsy that begins in infancy and early childhood and in many cases becomes intractable 4 . Intellectual disability and autism spectrum disorder occur in about half of TSC patients, with other psychiatric conditions prevalent 5 . The origins of the neurological aspects of TSC are not well understood; however, patients present with characteristic pathologies, called cortical tubers, which are macroscopic regions of disorganized and dysmorphic cells in the cortex 6 . Tubers and the perituberal cortex often become epileptic foci 7,8 and increased tuber load is correlated with more severe epilepsy and cognitive impairment 9 .
T uberous sclerosis complex (TSC) is a developmental disorder caused by mutations in the TSC1 or TSC2 genes 1, 2 . TSC affects multiple systems causing nonmalignant hamartomas that can affect the skin, heart, kidney, lung, and brain 3 . Among the most debilitating aspects of TSC are the neurological symptoms. Approximately 90% of TSC patients have epilepsy that begins in infancy and early childhood and in many cases becomes intractable 4 . Intellectual disability and autism spectrum disorder occur in about half of TSC patients, with other psychiatric conditions prevalent 5 . The origins of the neurological aspects of TSC are not well understood; however, patients present with characteristic pathologies, called cortical tubers, which are macroscopic regions of disorganized and dysmorphic cells in the cortex 6 . Tubers and the perituberal cortex often become epileptic foci 7, 8 and increased tuber load is correlated with more severe epilepsy and cognitive impairment 9 .
Work from mouse models indicates that loss of Tsc1 or Tsc2 from cortical progenitor cells results in altered neuronal differentiation, morphology, and migration [10] [11] [12] [13] [14] [15] , consistent with histological observations in patient tissue 6 . However, bona fide tubers are not found in rodent models 6, 11, 12, 16, 17 . This may be a result of differences between mouse and human cortical development. Human cortical neurogenesis occurs over a longer time (about 140 days in humans 18 compared with 8 days in mice 19 ), requires many more cell divisions, and exhibits unique proliferative zones and progenitor cell types 18, 20, 21 . Therefore, an experimental system that recapitulates early human cortical development is needed to understand the molecular and cellular origins of tubers.
At the biochemical level, the protein products of TSC1 and TSC2 form a heterodimeric protein complex that is an essential negative regulator of mechanistic target of rapamycin complex 1 (mTORC1) signaling 22 . mTORC1 is a kinase that controls key cellular processes including nutrient sensing, protein synthesis, and autophagy 23 . Two primary effectors of mTORC1 signaling are p70S6 kinase, which phosphorylates the ribosomal protein S6, and eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), which controls formation of the translation initiation complex 24 . TSC2 is a GTPaseactivating protein for the small GTP-binding protein Rheb, which is a direct activator of mTORC1 25 . TSC1 is required to stabilize TSC2 26 and loss of either protein disrupts TSC1-TSC2 complex function. In the absence of the TSC1-TSC2 complex, mTORC1 signaling is constitutively active, leading to alterations in cell growth, metabolism, and proliferation 27 .
The proposed model of cortical tuber formation is that somatic "second-hit" mutations in patients with heterozygous germ line mutations result in loss of function of the TSC1-TSC2 complex and hyperactivation of mTORC1 signaling in a subset of cortical progenitor cells 28, 29 . In line with this, there is clear evidence that loss of heterozygosity of TSC1 or TSC2 causes TSC-associated hamartomas including those in the brain, lung, and kidney [30] [31] [32] [33] [34] . However, second-hit mutations have only been observed in a minority of surgically resected cortical tubers from TSC patients 31, [35] [36] [37] , giving rise to the idea that haploinsufficiency may contribute to the neurological and cognitive aspects of TSC 38 . Here we investigate the developmental origins of tuber cells using two-(2D) and three-dimensional (3D) human neuronal cultures with engineered mutations in the TSC1 or TSC2 genes. We find that homozygous, but not heterozygous, loss of TSC1 or TSC2 profoundly affects the development of human cortical neurons and glia, giving rise to dysplastic cells resembling those found in tubers.
Tuberous sclerosis complex (TSC) is a multisystem developmental disorder caused by mutations in the TSC1 or TSC2 genes, whose protein products are negative regulators of mechanistic target of rapamycin complex 1 signaling. Hallmark pathologies of TSC are cortical tubers-regions of dysmorphic, disorganized neurons and glia in the cortex that are linked to epileptogenesis. To determine the developmental origin of tuber cells, we established human cellular models of TSC by CRISPR-Cas9-mediated gene editing of TSC1 or TSC2 in human pluripotent stem cells (hPSCs). Using heterozygous TSC2 hPSCs with a conditional mutation in the functional allele, we show that mosaic biallelic inactivation during neural progenitor expansion is necessary for the formation of dysplastic cells and increased glia production in three-dimensional cortical spheroids. Our findings provide support for the second-hit model of cortical tuber formation and suggest that variable developmental timing of somatic mutations could contribute to the heterogeneity in the neurological presentation of TSC.
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We verified by western blotting that homozygous mutant hESCs exhibited complete loss of TSC1 or TSC2 protein and heterozygous cells exhibited partial loss ( Fig. 1c-e, Supplementary Fig. 2 , and Supplementary Table 2 ). We observed a significant reduction in TSC2 protein in TSC1 −/− cells and TSC1 protein in TSC2 −/− cells, consistent with prior data showing that the TSC1 and TSC2 proteins stabilize each other and that in the absence of one protein, the other is degraded 26 . We examined the phosphorylation state of the mTORC1 pathway targets, ribosomal protein S6 and 4E-BP1, and found significant elevations in p-S6 in TSC2 −/− cells and p-4E-BP1 in TSC1 −/− and TSC2 −/− hESCs (Fig. 1c,f,h) . Total levels of S6 protein were also significantly increased in TSC1 −/− cells ( Fig. 1c, g) , consistent with mTORC1's role in promoting the synthesis of ribosomal proteins 39, 40 . Notably, hESCs with heterozygous mutations in TSC1 or TSC2 did not display activation of mTORC1 signaling (Fig. 1c ,f-i). 
Fig. 1 | Generation of heterozygous and homozygous knockout TSC1
and TSC2 heSc lines. a,b, CRISPR-Cas9-mediated targeting strategies for TSC1 (a) and TSC2 (b). Two sgRNAs (sgRNA1 and sgRNA2) were designed to target either side of exon 17 of TSC1 (a) or exon 5 of TSC2 (b). Excision of these exons causes a frameshift and premature stop codon. c, Representative western blots of hESC lysates from the indicated genotypes. Two hESC culture samples per genotype are shown; this experiment was replicated three times. Western blots were cropped to show the relevant bands and molecular weight (MW) markers are indicated on the right (in kD). See Supplementary Fig. 2 
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AKT (also called protein kinase B) is an upstream activator of mTORC1 that controls its activity through phosphorylation and inhibition of TSC2 41 . AKT and other upstream regulators of mTORC1 are subject to potent negative feedback regulation 41 . Consistent with engagement of a negative feedback pathway, we observed significantly reduced phosphorylation of AKT at Ser473 in both TSC1 −/− and TSC2 −/− hESCs, and a small but significant decrease in TSC1 +/− hESCs ( Fig. 1c,j) . Interestingly, we also observed increased total AKT protein in TSC1 +/− and TSC1 −/− hESCs, which was not observed in hESCs with TSC2 mutations (Fig. 1c,k) . Together, these results demonstrate that homozygous, but not heterozygous, disruption of TSC1 or TSC2 increases mTORC1 signaling and decreases AKT phosphorylation in hESCs.
Phenotypes of neural progenitor cells lacking TSC1 or TSC2.
To investigate how mutations in TSC1 or TSC2 affect early human neural development, we differentiated our panel of hESCs into 2D cultures of forebrain neural progenitor cells (NPCs) 42 . We found that nestin-positive NPCs could be generated from hESCs of all genotypes ( Supplementary Fig. 3a ). However, TSC1 −/− and TSC2 −/− NPCs were hypertrophic ( Supplementary Fig. 3a ,b), consistent with observations in other cell types exhibiting high mTORC1 signaling 23 . We observed a large increase in p-S6 in both TSC1 −/− and TSC2 −/− NPCs, with TSC2 −/− NPCs exhibiting significantly higher p-S6 levels than TSC1 −/− cells ( Supplementary Fig. 3c -f). TSC1 −/− NPCs displayed increased 4E-BP1 phosphorylation as well as total levels of S6 and 4E-BP1 ( Supplementary Fig. 3c ,g-i). We observed strongly reduced AKT (Ser473) phosphorylation in TSC2 −/− NPCs, and to a more variable extent in TSC1 −/− NPCs ( Supplementary  Fig. 3c,j) . In contrast to hESCs, total levels of AKT were reduced in TSC1 −/− and TSC2 −/− NPCs ( Supplementary Fig. 3c ,k).
3D cortical spheroid differentiation. The human cortex develops from neuroepithelial cell precursors that generate radial glia progenitors, which divide asymmetrically to produce excitatory neurons followed by astrocytes, a type of glia 18, 20 . To investigate how mutations in TSC1 or TSC2 affect neural development in a 3D tissue context that recapitulates this progression, we differentiated our panel of hESCs into cortical spheroids using an established protocol 43 ( Fig. 2a ). At 20 days post-differentiation, rosette structures resembling cortical ventricular zones could be observed in spheroids of all genotypes (Fig. 2b,c) . These structures contained cells that expressed the neural progenitor markers paired box protein Pax-6 (PAX6) and transcription factor SOX-2 (SOX2). There were no significant differences in the percentage of PAX6-or SOX2positive cells in spheroids derived from hESCs with mutations in TSC1 or TSC2 (Fig. 2d,e ), indicating that TSC mutations do not strongly affect differentiation into forebrain progenitors. We performed staining for the cell proliferation marker protein Ki-67 and found that 49.7 ± 5.5% of cells in wild-type (WT) spheroids were proliferating at day 20 ( Fig. 2c,f ). We did not find significant differences in the proportion of Ki-67-positive cells in spheroids with mutations in TSC1 or TSC2 (Fig. 2f ).
In WT spheroids, expression of neuronal markers including NeuN and microtubule-associated protein 2 (MAP2) began around day 30-50 post-differentiation and increased through day 150 ( Fig. 2g,h and Supplementary Fig. 4a ). Markers of glial lineage cells, which include astrocytes, emerged later with expression of glial fibrillary acidic protein (GFAP) and S100 calcium-binding protein B (S100B) beginning around day 100 and increasing through day 150, consistent with in vivo human cortical development 18 (Fig. 2g ,i and Supplementary Fig. 4b ). While spheroids with heterozygous mutations in TSC1 or TSC2 showed a normal profile of neuron and glia development ( Fig. 2g-m and Supplementary  Fig. 4a -f), TSC1 −/− and TSC2 −/− spheroids exhibited reduced or delayed expression of neuronal markers and increased expression of glial lineage markers. This was demonstrated by significantly reduced MAP2 and increased GFAP protein expression from days 100 to 150 in TSC2 −/− spheroids and on day 100 and 150, respectively, in TSC1 −/− spheroids ( Fig. 2g -i). mRNA levels showed a similar pattern with decreased RBFOX3 (NeuN) and increased S100B expression in TSC2 −/− spheroids on day 100 ( Fig. 2j ,k). TSC2 −/− spheroids also exhibited consistently reduced neuron/glia ratios on day 100, assessed by immunostaining for NeuN and S100B, although this did not reach statistical significance ( Fig. 2l and Supplementary Fig. 4c ). This may reflect biased differentiation into glial lineage cells as opposed to enhanced glial proliferation since we did not find significantly increased numbers of Ki-67/S100B double-positive cells in TSC1 −/− or TSC2 −/− spheroids ( Supplementary Fig. 4d,e ). The neurons and glia that were generated in TSC1 −/− and TSC2 −/− spheroids were enlarged, dysmorphic, and had high levels of p-S6 ( Fig. 2l,m and Supplementary Fig. 4e ,f), similar to those observed in TSC patient tubers 6 .
We verified that these phenotypes were not specific to the hESC line used for gene editing by using CRISPR-Cas9 to generate a homozygous deletion of TSC2 in an independent human induced pluripotent stem cell (hiPSC) line that we generated from BJ fibroblasts ( Supplementary Fig. 1i ,j and Supplementary Table 1 ). Similar to WIBR3 TSC2 -/spheroids, BJ TSC2 −/− spheroids exhibited enlarged, dysplastic neurons and glia that had high levels of p-S6 ( Supplementary Fig. 4g ,h). TSC1 −/− and TSC2 −/− spheroids fail to suppress mTORC1 during neurogenesis. To determine how loss of the TSC1-TSC2 complex loss might alter human neuron and glia development, we monitored mTORC1 signaling in WT and TSC2 −/− cortical spheroids over time ( Fig. 3a-g ). We found that both the total levels and phosphorylation of S6 were strongly reduced in WT spheroids as they transitioned from proliferating to differentiating, with the highest levels at day 0, when cells were still pluripotent ( Fig. 3a-c ). A similar pattern was observed for 4E-BP1 ( Fig. 3a,d ,e) suggesting that two downstream targets of mTORC1 signaling involved in translational control are strongly suppressed during human neural differentiation. Notably, although total levels of 4E-BP1 and S6 decreased between days 20 and 100 in TSC2 −/− spheroids ( Fig. 3c,e ), likely reflecting changes in cell type composition of the spheroids, the ratio of phosphorylated to total protein remained as high as in stem cells throughout spheroid development ( Fig. 3b,d ). This indicates that TSC2 −/− cells were unable to suppress mTORC1 signaling during neuronal differentiation. The hyperphosphorylation of the mTORC1 pathway targets in TSC2 mutant spheroids was in contrast to AKT phosphorylation, which was strongly reduced throughout development in TSC2 −/− spheroids ( Fig. 3f,g) .
Given the dynamic regulation of mTORC1 signaling we observed during cortical spheroid development, we quantitatively compared mTORC1 signaling across all genotypes at multiple developmental time points ( Supplementary Fig. 5a -g). Homozygous loss of TSC1 or TSC2 produced overall similar changes in mTORC1 signaling. However, TSC2 loss increased S6 phosphorylation to a greater extent than TSC1 deletion on days 20-100 post-differentiation ( Supplementary Fig. 5b ). The phosphorylation of 4E-BP1 was significantly increased over WT levels in TSC2 −/− spheroids on days 20-100 and in TSC1 −/− spheroids on days 30 and 50 ( Supplementary Fig. 5d ). By contrast, AKT phosphorylation was strongly reduced in TSC2 −/− spheroids at all time points and on days 20-100 in TSC1 −/− spheroids ( Supplementary  Fig. 5f ). Heterozygous spheroids exhibited a normal developmental pattern of mTORC1 signaling, with no significant differences in S6, 4E-BP1, or AKT phosphorylation at any time point compared to WT spheroids ( Supplementary Fig. 5a -g).
In addition to TSC1 and TSC2, the TSC complex contains a third requisite protein, TBC1 domain family member 7 (TBC1D7), 43 . b,c, Confocal images of day 20 cortical spheroid sections from the indicated genotypes, stained with antibodies against nestin (green) and PAX6 (red) (b) or tubulin beta-3 chain (TUJ1) (green), SOX2 (red), and Ki-67 (gray) (c). DAPI staining is in blue. Scale bars represent 25 μ m. The experiments in panels b and c were replicated three times (three separate differentiations). d-f, Bar graphs (mean ± s.e.m.) display quantification of PAX6-(d), SOX2-(e), or Ki-67-positive (f) cells expressed as a percentage of total DAPI-labeled cells in day 20 cortical spheroids. Dots represent data from individual spheroids, n = 3 spheroids per genotype from three separate differentiations. g, Representative western blots of wildtype (WT), TSC1 −/− , and TSC2 −/− cortical spheroids collected at different time points post-differentiation from hESCs (day 0). Western blots were cropped to show the relevant bands; molecular weight (MW) markers are indicated on the right (in kD). See Supplementary Fig. 2 for uncropped western blots. This experiment was replicated six times (three separate differentiations). h,i, Quantification of western blot results for the neuronal protein MAP2 (h) and the glial protein GFAP (i) across cortical spheroid development (mean ± s.e.m.). Day 0, n = 6 hESC cultures per genotype. Days 20-150, n = 6 spheroids per genotype per time point, from three separate differentiations. Two-way ANOVA P values are shown. Significant differences with Dunnett's multiple comparisons test are indicated by blue asterisks for WT versus TSC1 −/− (P MAP2 d100 = 0.0021, P GFAP d150 < 0.0001) and red asterisks for WT versus TSC2 −/− (P MAP2 d100 = 0.0003, P MAP2 d150 = 0.0018, P GFAP d100 = 0.0297, and P GFAP d150 = 0.0028). j,k, qPCR results (mean ± s.e.m.) for RBFOX3 (NeuN) (j) and S100B (k) mRNA in day 100 cortical spheroids. Dots represent individual spheroids, n = 7 spheroids per genotype from five separate differentiations. Data were analyzed with a one-way ANOVA followed by Sidak's multiple comparisons test: *P NeuN WT versus TSC2 −/− = 0.0461; **P S100B WT versus TSC2 −/− = 0.0029. l, Confocal images of day 100 cortical spheroid sections stained with antibodies against NeuN (green) and S100B (red). DAPI staining is in blue. Scale bars represent 25 μ m. This experiment was replicated three times (three separate differentiations). m, Confocal images of day 150 cortical spheroid sections stained with antibodies against MAP2 (green) and p-S6 (Ser240/244, red). DAPI staining is in blue. Scale bars represent 20 μ m. This experiment was performed once. See Supplementary Table 2 for sample sizes, sample definition, P values, F values, t-values, degrees of freedom, and confidence intervals for all comparisons. This experiment was replicated five times (three separate differentiations). Western blots were cropped to show the relevant bands; molecular weight (MW) markers are indicated on the right (in kD). See Supplementary Fig. 2 Articles NaTURe MedICINe which binds to TSC1 and is required for complex stability 44 . We measured protein levels of TBC1D7 in TSC1 −/− and TSC2 −/− spheroids over time and found that TBC1D7 was strongly reduced in TSC1 −/− spheroids from day 20 onwards, likely due to degradation in the absence of TSC1 protein ( Supplementary Fig. 5h ,i). We also observed smaller but significant reductions in TBC1D7 in TSC2 −/− spheroids compared to WT on days 20, 50, and 150 ( Supplementary  Fig. 5h ,i), which may reflect the approximately 60% loss of TSC1 protein in these cells. Taken together, these data demonstrate that mTORC1 signaling is strongly suppressed during human neuronal differentiation and that homozygous loss-of-function mutations in TSC1 or TSC2 prevent this developmental regulation.
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STAT3 phosphorylation is activated in TSC1 −/− and TSC2 −/− spheroids. The cortical radial glial lineage generates excitatory neurons first, followed by astrocytes. Studies in rodent models have shown that the gene expression programs that drive neuron and astrocyte differentiation are regulated by competitive cell-intrinsic and -extrinsic signals 45 . Since the strong developmental suppression of mTORC1 signaling that we observed in WT spheroids coincided with the time when neurogenesis begins, we hypothesized that mTORC1 signaling may promote gliogenic signals, which are normally suppressed to allow neurogenesis.
In rodent models, the JAK-STAT signaling pathway induces astrocyte differentiation from cortical precursor cells 46 . Specifically, activation of signal transducer and activator of transcription 3 (STAT3) promotes the transcription of genes involved in astrocyte differentiation including gfap 46 . We investigated the phosphorylation of STAT3 at two key residues, Ser727 and Tyr705, in WT, TSC1 −/− , and TSC2 −/− cortical spheroids over time. We found that Ser727 was high in hESCs and reduced in all genotypes during neural differentiation ( Fig. 3h,i) . By contrast, Tyr705 was low in hESCs and increased in WT spheroids from days 100 to 150 when astrocytes begin to appear ( Fig. 3h,j) . Notably, TSC1 −/− and TSC2 −/− spheroids exhibited increased p-STAT3 (Tyr705), an effect that was most pronounced in TSC2 −/− spheroids ( Fig. 3j ). Total STAT3 levels did not change significantly with development or TSC1 or TSC2 loss ( Fig. 3h,k) .
The increased p-STAT3 (Tyr705) was mTOR-dependent as it was strongly reduced in day 100 TSC2 −/− spheroids treated chronically with the mTOR inhibitor rapamycin (20 nM, treatment started on day 12 of differentiation, 49.9 ± 23.7% of vehicle control; Supplementary  Fig. 5j ). Rapamycin also strongly reduced the expression of GFAP (4.4 ± 1.6% of control) and increased the expression of neuronal proteins including neuronal migration protein doublecortin (DCX) (348.1 ± 15.9% of control), calcium/calmodulin-dependent protein kinase type II subunit alpha (CAMK2A) (193.8 ± 48.3% of control), and glutamate receptor 1 (GLUA1) (153.1 ± 22.1% of control) in TSC2 −/− spheroids ( Supplementary Fig. 5j ). These data support the idea that mTORC1 signaling is gliogenic and are consistent with a previous report in mice showing that genetic inactivation of mTORC1 suppresses cortical gliogenesis 47 .
Engineering a conditional TSC2 allele to model a second-hit mutation. Our results in 2D and 3D human neural cultures indicated that homozygous loss of TSC1 or TSC2 profoundly affects the developmental regulation of mTORC1 signaling, cell morphology, and neuronal and glial differentiation. Notably, we found minimal to no alterations in heterozygous cells. These results are consistent with the idea that tuber cells arise from a somatic second-hit mutation that causes biallelic inactivation of TSC1 or TSC2. To test this, we generated a model that recapitulates a second-hit mutation by engineering hESCs with a conditional allele of TSC2. This cell line has a constitutive loss-of-function mutation in one allele and a Cre-inducible conditional mutation in the second allele (TSC2 −/c ; Fig. 4a and Supplementary Fig. 1b ). We chose to target TSC2 because the majority of patient mutations are in TSC2 48 and homozygous loss of TSC2 generally caused more severe phenotypes compared to TSC1 (see Figs. 2, 3 and Supplementary Figs. 3 and 5 ). We confirmed that viral delivery of Cre recombinase to neurons differentiated in 2D from TSC2 −/c hESCs resulted in loss of TSC2 protein and upregulation of mTORC1 signaling (Fig. 4b) . To allow for the visualization and fate mapping of Cre-expressing cells, we generated a tdTomato Cre reporter allele in the TSC2 −/c hESCs by targeting the adenoassociated virus integration site 1 (AAVS1) "safe harbor" locus 49 with CRISPR-Cas9. (We refer to this cell line as TSC2 −/c;LSL-tdTom ; see Fig. 4c .) We validated the pluripotency of TSC2 −/c;LSL-tdTom hESCs with POU domain, class 5 transcription factor 1 (OCT4) and homeobox protein NANOG immunostaining and teratoma formation assays ( Supplementary Fig. 1h ,m-r).
To test how biallelic inactivation of TSC2 cell autonomously affects neuronal development, we differentiated TSC2 −/c;LSL-tdTom hESCs, treated with Cre just before differentiation, into 2D cultures of NPCs and neurons 42 (Fig. 4d,e ). We found that Cre-expressing, tdTomato-positive cells, which had homozygous loss of TSC2, exhibited significantly increased p-S6 levels compared to neighboring green fluorescent protein (GFP)-expressing heterozygous 
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NaTURe MedICINe cells (Fig. 4f,g and Supplementary Fig. 6a,b) . tdTomato-positive cells were also enlarged compared to neighboring cells (Fig. 4h,i) . In addition to soma enlargement, neurons with a second-hit TSC2 mutation exhibited significant dendritic hypertrophy measured by Sholl analysis (Fig. 4j ). We also observed highly enlarged, multinucleated tdTomato-positive TSC2 mutant cells that resembled "giant cells"-a unique cell type found in TSC patient tubers 6 ( Supplementary Fig. 6c ). Multiple nuclei were not observed in TSC2 heterozygous cells. These results demonstrate that cell-autonomous changes in mTORC1 signaling are sufficient to cause enlarged and dysmorphic cells resembling those found in tubers.
Biallelic inactivation of TSC2 in cortical spheroids.
To test whether biallelic inactivation of TSC2 in developing cortical spheroids causes the formation of dysplastic cells, we differentiated TSC2 −/c;LSL-tdTom hESCs into cortical spheroids and treated them with a subsaturating amount of Cre and GFP virus on day 12 postdifferentiation, during the neural progenitor expansion phase. We a c Articles NaTURe MedICINe confirmed that tdTomato-positive NPCs in cortical spheroids were enlarged ( Supplementary Fig. 6d,e ), consistent with complete loss of TSC2 and activation of mTORC1. We found that Cre-expressing TSC2 −/c cells gave rise to highly dysmorphic neurons, glial lineage cells, and giant cells that became larger over time (Fig. 4k-o and Supplementary Fig. 6f-h) . These cells were phenotypically similar to those observed in cortical tubers from TSC patients 6, 50 . Specifically, the cells were hypertrophic and dysplastic with high levels of p-S6 and diffuse cytoplasmic expression of filament proteins including nestin and vimentin (Fig. 4k-o and Supplementary Fig. 6f,g) . In addition, some tdTomato-positive TSC2 −/c cells coexpressed neuronal (MAP2) and glial (S100B) proteins ( Supplementary Fig. 6h ), which has been observed in patient tuber cells 50 . Importantly, cytomegalic cells did not develop in Cre-treated TSC2 +/c spheroids ( Supplementary Fig. 6i ), indicating that biallelic inactivation of TSC2 is required for the formation of dysplastic cells. We next tested whether a second-hit mutation is required for dysplastic cells to form in the context of TSC patient cells. To do this we reprogrammed fibroblasts from a TSC patient (Coriell Institute cell line GM04520) into hiPSCs ( Supplementary Fig. 1k and Supplementary Table 1 ). This patient has a heterozygous deletion of exons 1-14 of TSC2 ( Supplementary Fig. 7a ) and a history of childhood seizures and mild intellectual disability. To generate a conditional second-hit allele, we first deleted exon 5 of the patient's WT TSC2 allele using CRISPR-Cas9 and then introduced a conditional exon 5 allele using the same strategy as for TSC2 −/c hESCs ( Supplementary Fig. 7b,c) . The resulting hiPSC line had the patient mutation in one TSC2 allele and a conditional loss-of-function mutation in the second allele (referred to as 4520 −/c , Supplementary  Fig. 1l and Supplementary Table 1 ). 4520 −/c hiPSCs were differentiated into cortical spheroids and Cre-GFP virus was added 12 days post-differentiation. On day 100, we found that Cre-expressing cells were dysmorphic, had high levels of p-S6, and were positive for vimentin ( Supplementary Fig. 7d ). Neighboring uninfected cells did not exhibit the characteristics of tuber cells, indicating that biallelic inactivation is necessary for dysplastic cell formation in TSC patient-derived cortical spheroids.
Rescue of neuronal differentiation and morphology with rapamycin treatment.
To test whether the formation of dysplastic cells in TSC2 −/c;LSL-tdTom cortical spheroids could be prevented or rescued by blocking mTORC1 signaling, we treated spheroids with rapamycin at different time points during development ( Supplementary Fig. 8a ). For all conditions, subsaturating amounts of Cre and GFP virus were added on day 12 and spheroids were collected on day 110.
We found that chronic rapamycin starting on day 12 strongly reduced mTORC1 signaling in both heterozygous and homozygous TSC2 mutant cells and prevented cellular hypertrophy induced by biallelic TSC2 inactivation (Fig. 5a-e and Supplementary Fig. 8b,c) . To assess neuronal differentiation, we calculated the percentage of tdTomato (Cre) or GFP-positive TSC2 −/c cells that expressed the neuronal marker HuC/HuD or the glial protein S100B on day 110 ( Fig. 5d,e ). For GFP-labeled TSC2 heterozygous cells, 15.8% of cells expressed HuC/HuD, 34.2% expressed S100B, and 50% were not labeled by either marker (Fig. 5h ). The unlabeled cells likely represent neural progenitors or immature neurons and glia. Consistent with findings in the constitutive TSC2 −/− spheroids, tdTomato-positive TSC2 homozygous mutant cells preferentially generated glial lineage cells over neurons at a ratio of 7.3:1 (72.6% S100B positive versus 9.9% HuC/HuD-positive, Fig. 5i ). We confirmed that the majority of tdTomato-positive cells were likely astrocytes by immunostaining them with additional astrocyte markers including excitatory amino acid transporter 1 (EAAT1) and CD44 antigen ( Supplementary  Fig. 8f,g) . Chronic rapamycin starting on day 12 completely reversed the glial differentiation bias, causing tdTomato-positive TSC2 −/c cells to generate neurons at the expense of astrocytes (9.9% S100B-positive versus 70.4% HuC/HuD-positive, Fig. 5i ). Chronic rapamycin also nearly tripled the percentage of neurons generated by GFP-positive cells (from 15.8 to 46.5% HuC/HuDpositive, Fig. 5h ). These findings are consistent with our western blot results with rapamycin-treated TSC2 −/− spheroids (see Supplementary Fig. 5j ), indicating that suppression of mTOR signaling acts downstream of the TSC1-TSC2 complex to promote neuronal differentiation and inhibit or delay glial lineage cell production.
To test whether rapamycin treatment could reverse the phenotypes of TSC2 loss, we treated spheroids with rapamycin starting on day 80. Chronic rapamycin from day 80 to 110 strongly reduced mTORC1 signaling and reversed cellular hypertrophy to a similar extent as day 12-110 rapamycin treatment (Fig. 5a-f and Supplementary Fig. 8b-d) . Rapamycin from day 80 to 110 also improved the neuronal differentiation of tdTomato-positive TSC2 −/c cells (from 9.9 to 22.3% HuC/HuD-positive, Fig. 5i) ; however, the effect was more modest compared to day 12-110 treatment. Rapamycin from day 80 to 110 had little effect on neuronal differentiation in GFP-positive cells (15.8 versus 22.1% HuC/HuD-positive, Fig. 5h ). These results suggest that (1) the majority of neuronal cell fate decisions are made before day 80 in the cortical spheroid model and (2) rapamycin treatment cannot reverse this decision.
Based on these findings, we tested whether rapamycin treatment during the primary period of neuronal differentiation (from day 12 to 80) could prevent phenotypes due to homozygous loss of TSC2. We found that rapamycin treatment from day 12 to 80 improved neuronal differentiation in tdTomato-positive TSC2 −/c cells (from 9.9 to 30.3% HuC/HuD-positive), albeit to a lesser degree than in spheroids continuously treated with rapamycin ( Fig. 5e,g,i) . Despite improvements in neuronal differentiation, when rapamycin was withdrawn at day 80, tdTomato-positive TSC2 −/c cells reactivated mTORC1 signaling to a similar level as vehicle-treated mutant cells ( Fig. 5a and Supplementary Fig. 8b,e ).
Taken together, these results suggest that there is a developmental window for pharmacological mTORC1 suppression to prevent neuronal differentiation defects caused by loss of TSC2. Later rapamycin treatment cannot reverse cell fate decisions that have already been made, but can rescue mTORC1 hyperactivation and reduce neuronal and glial hypertrophy. Sustained mTORC1 inhibition is required to prevent the re-emergence of mTORC1 hyperactivity in differentiated cells.
Discussion
In this study, we generated a panel of hPSC lines with targeted lossof-function mutations in the TSC1 and TSC2 genes and used this genetically controlled system to investigate the contributions of TSC-mTOR signaling to human cortical development. We found that mTORC1 signaling is strongly suppressed during human neuronal differentiation and that this is required for normal neurogenesis and gliogenesis. Homozygous, but not heterozygous, loss of TSC1 or TSC2 disrupts the developmental suppression of mTORC1 signaling resulting in abnormal differentiation and hypertrophy of human neurons and glia. We provide support for the second-hit hypothesis of cortical tuber formation, as biallelic inactivation of TSC2 in NPCs was necessary and sufficient to cause the formation of dysplastic cells in human cortical spheroids. Finally, we demonstrate that mTOR inhibition during a critical developmental period promotes neuronal differentiation and prevents cellular hypertrophy.
A major finding of our study is that bidirectional changes in mTORC1 signaling profoundly affect the balance of neurons and glia in developing human cortical spheroids. Specifically, mTORC1 hyperactivation resulted in greater production of glial lineage cells, which include astrocytes, at the expense of neurons. By contrast, mTORC1 suppression strongly promoted neurogenesis and impaired gliogenesis. These effects were observed both in cortical spheroids with constitutive mutations in TSC2 and in cells with Articles NaTURe MedICINe a second-hit TSC2 mutation, which generated seven times more glia than neurons. The latter result suggests a cell-autonomous change in cell fate decision, as neighboring TSC2 heterozygous cells produced higher neuron/glia ratios. These findings are consistent with histological observations of large numbers of astrocytes in cortical tubers 6, 51 , mouse studies demonstrating increased GFAP Table 2 for sample sizes and exact P values for all comparisons. d-g, Representative confocal images of HuC/HuD and S100B immunostained sections from day 110 TSC2 −/c;LSL-tdTom spheroids treated with vehicle (d), rapamycin from days 12-110 (d12, e), rapamycin from days 80-110 (d80, f), or rapamycin from days 12-80 (d12-80, g). Scale bars represent 25 μ m. This experiment was replicated in 2 spheroids for vehicle, 3 spheroids for Rap d12, 3 spheroids for Rap d80, and 4 spheroids for Rap d12-80. h,i, The graphs display the percentage of GFP-(h) or Cre-positive (i) cells expressing HuC/HuD ("neuron", dark blue), S100B ("glia", red), both markers ("double-labeled", light blue), or neither marker ("unlabeled", gray) for each rapamycin condition. See Supplementary Table 2 for the sample sizes for each condition.
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NaTURe MedICINe expression following loss of Tsc1 or Tsc2 10, 13, 14 , and recent studies showing reduced neuronal and increased glial markers in 2D human TSC2 −/− neural cultures 52, 53 .
In the developing human cortex, early neuroepithelial progenitors give rise to radial glia, which can divide symmetrically to produce more radial glia, or asymmetrically to produce a neuron or an astrocyte 18, 21 . The mechanisms underlying neuron-astrocyte cell fate decisions in the human cortex are not well understood; however, studies in animal models have identified a cascade of intrinsic and extrinsic signaling events that govern time-dependent shifts from progenitor self-renewal to neurogenesis to gliogenesis 45 . Our findings demonstrate that suppression of mTORC1 signaling during the transition from proliferation to neuronal differentiation (between day 25 and 43 in the cortical spheroid model) is required for normal neurogenesis.
Mechanistically, mTORC1 could be inhibiting neurogenic gene expression programs, activating gliogenic signaling pathways, or increasing glial proliferation. In contrast to a study using 2D neural cultures derived from a TSC patient hiPSC line 54 , we did not find significant increases in the proportion of actively dividing glia in cortical spheroids with TSC mutations. Instead, we found that Tyr705 phosphorylation of the gliogenic transcription factor STAT3 was significantly elevated in TSC1 −/− and TSC2 −/− cortical spheroids in a rapamycin-sensitive manner, consistent with previous observations in 2D mouse and human neural cultures 10, 13, 52 . Importantly, we found that p-STAT3 levels were increased before the onset of neurogenesis in TSC mutant spheroids. Since neurogenic and gliogenic signals suppress one another, the activation of STAT3 may directly promote gliogenesis, while at the same time interfering with or delaying neurogenesis. In addition to increased glial cell production, it is also possible that high mTORC1 signaling may impair the survival of newborn neurons 10, 53 , further contributing to an altered neuron/glia ratio.
Our finding that rapamycin treatment early in cortical spheroid development alters cell fate decisions, including in TSC2 +/− cells, has important clinical implications. Rapamycin derivatives called rapalogues are used clinically to treat TSC and related disorders 28 , and it has been suggested that prenatal rapalogue treatment could be beneficial to prevent developmental abnormalities in TSC. We find that strong mTORC1 suppression alters the normal pattern of cortical differentiation. This suggests that prenatal rapamycin, while effective at preventing cellular phenotypes caused by mTORC1 hyperactivation, may be detrimental to the developing brain, consistent with behavioral studies in mice exposed to rapamycin in utero 55 . Our models will facilitate further testing of therapeutics for TSC and allow the definition of critical windows for treatment to have the most impact without causing detrimental outcomes.
Here we provide causal evidence that second-hit mutations are necessary and sufficient to generate dysplastic cells in developing human cortical spheroids. While this has been proposed to occur 28, 29 , second-hit mutations have only been detected in a subset of cortical tubers examined 31, [35] [36] [37] . This is in contrast to TSC-related hamartomas, including subependymal giant cell astrocytomas, in which second-hit events are frequently observed [30] [31] [32] [33] [34] . Using conditional TSC2 knockout hESCs and patient-derived hiPSCs, we have shown that a sporadic second-hit mutation in TSC2 −/c NPCs causes the formation of dysplastic cells in human cortical spheroids. These cells are strikingly similar to those observed in TSC patient tubers. Specifically, we found cell types resembling dysmorphic neurons, dysplastic glia, and giant cells that are hypertrophic and have high levels of mTORC1 signaling 50 . These cells express many of the same markers that have been observed in patient tubers 6 . Importantly, we did not observe tuber cell features in heterozygous TSC1 or TSC2 cells, or in TSC2 +/c cells treated with Cre, demonstrating that biallelic inactivation is necessary for the generation of dysplastic cells.
One possible reason that second-hit mutations have not been consistently identified in TSC patient brain tissue is that tubers comprise a mixture of cell types of different origin. Tubers contain dysmorphic cells with high mTORC1 activity as well as normalappearing neurons and glia. Additionally, immune cells infiltrate the tubers 56 , further diluting the number of cells with biallelic inactivation. Thus, low allelic frequency may have hindered the identification of somatic mutations. Indeed, in a recently reported focal cortical dysplasia case with a second-hit mutation in TSC2, the somatic mutation was present in only ~7% of brain cells 57 . Alternatively, mutations may occur in introns 58 , promoters, or other regulatory regions, or could be large copy number variants, which are not detectable by exome sequencing.
Taken together, our findings support the model that second-hit somatic mutations in small populations of NPCs give rise to the dysplastic cells that comprise cortical tubers. Such a stochastic mechanism can explain the large heterogeneity in tuber number and size among TSC patients. Since higher tuber load is linked to increased severity of epilepsy and intellectual disability, somatic mosaicism may be a key factor underlying the significant heterogeneity in the presentation of neurological phenotypes in TSC patients.
URLs. ImageJ, Image Processing and Analysis in Java, https:// imagej.nih.gov/ij/.
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Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41591-018-0139-y.
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Methods
Stem cell research was approved by the University of California, Berkeley Stem Cell Research Oversight Committee. Animals were used in accordance with protocols approved by the University of California, Berkeley Animal Care and Use Committee. See the Reporting Summary for additional details about experimental design, cell lines, and reagents used in this study. hESC cell culture. WIBR3 hESCs (NIH stem cell registry 0079) were obtained from Dr. Rudolf Jaenisch's laboratory and authenticated as reported in Lengner et al. 59 ; hESC culture was carried out as previously described 60 . Briefly, all hESC lines were maintained on a layer of inactivated mouse embryonic fibroblasts (MEFs, CD-1 strain, Charles River) in hESC medium composed of DMEM/F12 (Thermo Fisher Scientific) supplemented with 20% KnockOut Serum Replacement (KSR) (Thermo Fisher Scientific), 2 mM L-glutamine (Thermo Fisher Scientific), 1% nonessential amino acids (Thermo Fisher Scientific), 0.1 mM 2-mercaptoethanol (Thermo Fisher Scientific), 1,000 U ml −1 penicillin-streptomycin (Thermo Fisher Scientific), and 4 ng ml −1 fibroblast growth factor (FGF)-Basic (AA 1-155) recombinant human protein (Thermo Fisher Scientific). Cultures were passaged every 7 days with collagenase type IV (1.5 mg ml −1 ; Thermo Fisher Scientific) and gravitational sedimentation by washing 3 times in wash media composed of DMEM/F12 supplemented with 5% fetal bovine serum (FBS, Thermo Fisher Scientific) and 1,000 U ml −1 penicillin/streptomycin. All hESC lines were tested monthly for Mycoplasma contamination. hiPSC reprogramming. TSC patient (Coriell Institute cell line GM04520, referred to here as "4520") and control BJ fibroblasts (ATCC CRL-2522) were reprogrammed into iPSCs using a commercial kit that delivers the reprogramming factors via an mRNA-based system 61 (Stemgent). After reprogramming, cell lines were validated by expression of pluripotency markers and array comparative genomic hybridization (aCGH) analysis ( Supplementary Fig. 1 and Supplementary  Table 1 ). The patient TSC2 genotype was confirmed by quantitative PCR (qPCR) ( Supplementary Fig. 7a ). All hiPSC lines were tested monthly for Mycoplasma contamination. Supplementary  Table 3 ) targeting the genomic region of interest were inserted into the CRISPR-Cas9-encoding px330 plasmid 62 . Following trypsinization with trypsin-EDTA buffer (Thermo Fisher Scientific), 15 µ g of each px330 plasmid, and 7.5 µ g of a GFP-encoding plasmid were electroporated into approximately 1 × 10 7 hESCs and replated onto MEFs as previously described 60 . After 72 h, cells underwent FACS to obtain 1 × 10 5 GFP-positive single cells and were then replated. After 12 days, 48-72 single-cell-derived hESC colonies were manually picked and replated onto individual wells. After 7 days, colonies were picked and replated, with the remaining cells genotyped using PCR. Genotyping primers are listed in Supplementary Table 3 . The same sgRNAs and genotyping strategy used to create the TSC2 +/− WIBR3 hESCs were used to create homozygous deletion of TSC2 exon 5 in the BJ hiPSC line.
CRISPR-Cas9 genome editing. Single-guide RNAs (sgRNAs; see
To generate a conditional allele of TSC2, we inserted an exon 5 cassette that was flanked by loxP sites into TSC2 +/− hESCs. To do this we cloned a new sgRNA targeting the nonhomologous end joining junction into px330. A repair plasmid consisting of 500 bp long homology arms, exon 5 surrounded by loxP sites, and a puromycin resistance cassette flanked by flippase recognition target (FRT) sites was created; 15 µ g of the px330 and 35 µ g of the repair plasmid were electroporated into the desired cells and replated onto MEFs generated from DR-4 mice (Jackson Laboratories, strain 003208). After 72 h, puromycin dihydrochloride (0.5 μ g ml −1 ; Thermo Fisher Scientific) was added to the hESC medium for the next 7 days. Surviving single-cell-derived colonies were manually picked and replated. Genotyping was repeated as described earlier to confirm the insertion of the puromycin cassette and the reinsertion of the exon through homology-directed repair (HDR). The puromycin resistance cassette was then removed through transfection of Flp recombinase mRNA (Miltenyi Biotec) with a Stemfect RNA Transfection Kit (Stemgent) and subsequent single-cell-derived colony isolation and genotyping. To create the TSC2 −/c cell line, the WT exon 5 was excised using the same CRISPR-Cas9 strategy as described earlier; 4520 −/c hiPSCs were generated using the same approach.
The tdTomato Cre reporter cassette was based on the Ai9 construct generated by Dr. Hongkui Zeng 63 (Addgene plasmid 22799). The reporter cassette was inserted into the AAVS1 "safe harbor" locus 64 , after exon 1 of the PPP1R12C gene, using the same HDR genome editing methods described earlier. The STOP cassette (3× STOP-SV40 polyA) was excised in the presence of Cre recombinase, allowing the expression of tdTomato from the CAGGS promoter. tdTomato is expressed in all of the progeny of cells initially infected with the Cre lentivirus. All gene-edited hPSC lines were validated by expression of pluripotency markers and aCGH analysis ( Supplementary Fig. 1 and Supplementary Table 1 ).
Teratoma formation. TSC2 −/c;LSL-tdTom hESCs were collected by collagenase treatment (1 mg ml −1 ) and separated from feeder cells by sedimentation. Cells were resuspended in 250 μ l of DMEM + 5% FBS and injected subcutaneously into adult nonobese diabetic-severe combined immunodeficiency mice (Taconic Biosciences). Teratomas formed within 4-8 weeks, at which time teratomas were isolated, fixed in formalin, and embedded in paraffin followed by sectioning and hematoxylin and eosin staining. Whole teratoma images were collected on a ZEISS Axio Scan.Z1 slide scanner microscope (Plan Apo 20 × /0.8 NA). blocked in 5% milk in tris-buffered saline (TBS)-Tween 20 for 1 hour at room temperature, and incubated with primary antibodies diluted in 5% milk in TBS-Tween 20 overnight at 4° C. The following day, membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (Bio-Rad) for 1 hour at room temperature, washed, incubated with Western Lightning Plus-ECL, Enhanced Chemiluminescence Substrate (Perkin-Elmer), and developed on GE Amersham Hyperfilm ECL (VWR). Membranes were stripped with 6 M guanidine hydrochloride (Sigma-Aldrich) to re-blot on subsequent days. Bands were quantified by densitometry using ImageJ software (see URLs). Phosphoproteins were normalized to their respective total proteins and non-phosphoproteins were normalized to a β -actin loading control. Antibody vendors, catalog numbers, and dilutions are listed in Supplementary Table 4 . Vendors and catalog numbers for all other reagents are listed in Supplementary Table 5 .
Immunocytochemistry on 2D cultured cells. Cells plated onto 12 mm glass coverslips were washed in ice-cold 1× PBS with Ca/Mg followed by fixation for 10 mins in 4% paraformaldehyde (PFA, VWR) and three 5-min washes in 1× PBS. Coverslips were blocked for 1 hour at room temperature in buffer containing 5% normal goat serum (NGS) (Thermo Fisher Scientific) and 0.3% Triton X-100 in 1× PBS and incubated in primary antibodies in antibody dilution buffer (1% BSA and 0.3% Triton X-100 in 1× PBS) overnight at 4 °C. The following day, coverslips were washed three times for 5 min in 1× PBS, incubated with secondary antibodies in antibody dilution buffer (1:500) for 1 hour at room temperature and washed three times for 5 min in 1× PBS. Coverslips were mounted onto slides with ProLong Gold Antifade Mountant with or without 4,6-diamidino-2-phenylindole (DAPI, Thermo Fisher Scientific) and allowed to set for one day before imaging. Antibody vendors, catalog numbers, and dilutions are listed in Supplementary Table 4 .
Immunohistochemistry on 3D spheroids. Spheroids were removed from growth media and washed once in ice-cold 1× PBS with Ca/Mg before being fixed in 4% PFA overnight at 4 °C. After fixation, spheroids were placed into a conical tube containing 30% sucrose solution overnight at 4 °C and allowed to settle. The following day, spheroids were frozen in tissue blocks with OCT compound (Thermo Fisher Scientific) and sectioned on a cryostat into 10 or 16 μ m sections. Sections were washed once with PBS and blocked in buffer containing 10% NGS, 0.1% BSA, and 0.3% Triton X-100 in 1× PBS for 1 hour at room temperature. Sections were then incubated overnight at 4 °C in primary antibodies in antibody dilution buffer (2% NGS and 0.1% Triton X-100 in 1× PBS). The following day, sections were washed three times with 1× PBS, incubated in secondary antibody (1:500 in antibody dilution buffer) for 1 hour at room temperature and washed again three times with 1× PBS. Slides were coverslipped with ProLong Gold Antifade Mountant with or without DAPI and allowed to set for 1 day before imaging. Antibody vendors, catalog numbers, and dilutions are listed in Supplementary Table 4 .
qPCR. RNA was extracted from whole spheroids using an RNeasy kit (Qiagen) with an on-column DNAse digestion. RNA levels and purity were assessed with a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific). Reverse transcription was performed using random hexamer primers and SuperScript III reverse transcriptase (Thermo Fisher Scientific). Real-time PCR was performed in triplicate on 600 ng of cDNA using a QuantStudio 6 Flex Real-Time PCR System (Applied Biosystems) with SYBR FAST qPCR Master Mix (Kapa Biosystems). Values for all genes were normalized to β -actin for each sample; qPCR primer sequences are listed in Supplementary Table 3 .
Lentiviral infection.
Human cytomegalovirus (CMV) promoter-driven Cre-GFP, Cre-red fluorescent protein (RFP), and/or GFP lentivirus (Kerafast; titer > 1.0 × 10 8 CFU ml −1 ) were added to cell culture media at the indicated time points. For high efficiency infection for the western blot experiments, 2.0 μ l per well was used in 24-well plates. For sparse infection, 0.25-0.5 μ l per well was used in 6-well plates. This amount of Cre-GFP or Cre-RFP virus resulted in Cre expression in approximately 5-15% of the cells in the spheroid or 2D culture. Sholl analysis. Cultured 2D TSC2 −/c;LSL-tdtom neurons were treated with Cre lentivirus on day 5 of neural induction and fixed on day 75. Coverslips were stained with MAP2 antibody and subsequently imaged. Multiple cells per coverslip were traced by hand using the MAP2 channel. Cell traces were imported into ImageJ (see URLs) and analyzed using the built-in Sholl analysis feature. Concentric circles of 5 µ m up to 160 µ m from the center of the soma were used for quantification of dendritic intersections.
Rapamycin treatment.
A quantity of 20 mM rapamycin (LC Laboratories) stock solution was prepared in ethanol and stored at − 20 °C. Rapamycin stock was diluted to a final concentration of 20 nM and added to the spheroids during every media change for the time periods indicated. Ethanol vehicle was added in the same concentration to the control samples.
Confocal microscopy and image analysis. Images were taken on either an FV1000 Olympus Fluoview confocal microscope with 10× or 20× objectives (Nikon) or a ZEISS Laser Scanning Microscope 719 AxioObserver with 20× or 40× objectives. For experiments where two or more conditions were quantitatively compared, the same exposure and acquisition settings were used for each image. All images were processed using the ImageJ software (see URLs). Only healthy regions of the spheroids, defined by intact DAPI nuclei, were used for quantification and analysis. To assess cell body size, regions of interest (ROIs) were drawn around each cell in Image J. ROIs were saved and applied to the p-S6 images where the mean fluorescence units averaged across the ROI were used as the p-S6 value for that cell. For images analyzed for the presence or absence of cellular markers, a threshold was set based on the background fluorescence level and applied to all ROIs. If the mean fluorescence units averaged across the ROI were above the threshold, the cell was considered positive for the marker. For the analysis of cell fate in Fig. 5 , cells were analyzed from 2-4 spheroids per condition (as indicated in Supplementary  Table 2 ) and the percentage of HuC/HuD-and/or S100B-positive cells out of the total population of GFP or tdTomato-positive cells analyzed was quantified.
Statistics summary. Sample sizes were chosen based on previous studies. All samples were included in the analysis. Spheroids were randomly assigned to the rapamycin or vehicle treatment groups. The investigator was blind to genotype for image analysis of constitutive spheroids. Other quantifications were not performed blindly. Statistical analysis was performed using the GraphPad Prism 6 software (GraphPad software) for Windows and the specific test for each experiment is noted in the figure legend and in Supplementary Table 2 . To compare the means of two normally distributed groups, an unpaired two-tailed t-test was used. To compare the distributions between two groups, a Kolmogorov-Smirnov test was used. To compare the means of three or more groups, a one-way analysis of variance (ANOVA) was used followed by Bonferroni's or Sidak's multiple comparisons test. For data sets with three or more groups with nonnormal distributions or different numbers of samples per condition, a Kruskal-Wallis test was used followed by Dunn's multiple comparisons test. To compare two independent variables, a two-way ANOVA was used with Dunnett's or Tukey's multiple comparisons test. Reported P values are adjusted for multiple comparisons for experiments with three or more groups. Supplementary Table 2 lists the  statistical test, sample 
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